Mymd Pharmaceuticals, Inc. (NASDAQ:QCLS) Stock Short Interest Drops 50.2%

Mymd Pharmaceuticals, Inc. (NASDAQ:QCLS) saw a significant decrease in short interest in the month of September. As of September 30th, there was short interest totaling 947,657 shares, a decrease of 50.2% from the September 15th total of 1,904,283 shares. Currently, 11.7% of the company’s shares are short sold. Based on an average trading volume of 26,546,756 shares, the short-interest ratio is presently 0.0 days.

Mymd Pharmaceuticals Stock Down 2.7%

QCLS stock traded down $0.01 during mid-day trading on Wednesday, hitting $0.53. 95,492 shares of the company were exchanged, compared to its average volume of 2,124,176. The stock has a market capitalization of $4.36 million, a price-to-earnings ratio of -0.15 and a beta of 2.32. The firm’s fifty day simple moving average is $1.67. Mymd Pharmaceuticals has a 12-month low of $0.42 and a 12-month high of $8.17.

Mymd Pharmaceuticals (NASDAQ:QCLS) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.79) earnings per share for the quarter.

Analysts Set New Price Targets

A number of equities research analysts have commented on QCLS shares. Wall Street Zen upgraded Mymd Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 19th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Mymd Pharmaceuticals in a report on Friday, August 7th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company currently has an average rating of “Sell”.

About Mymd Pharmaceuticals

MyMD Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated diseases, inflammation and age-related conditions. The company has historically pursued treatments designed to regulate the immune system and address biological processes associated with chronic disease and aging.

MyMD’s principal investigational product has been MYMD-1, an orally administered small-molecule therapy intended to modulate immune and inflammatory responses.